Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination
New series on Key Trends in Oncology for 2018
People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...
The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?